Good MorningEquity markets retreated on Thursday after a hot reading of the Produce Price Index raised fears that higher-for-longer means what it sounds like. The PPI accelerated at the core and headline levels, suggesting that consumer-level inflation will remain hot. In this environment, it is unlikely the FOMC will cut rates before mid-summer, and the first cut may not come until late in the year.
The risk for markets is the outlook for earnings. The market has priced in a significant upswing in earnings power for the back half of 2024 that may not come. This has the market set up for a correction that could be severe, given the proper stimulus. The catalyst for the correction may be in the earnings forecasts, which are expected to fall from their current levels. With only a few weeks left until the start of Q1 reporting, it is possible that the catalyst could come soon. Featured: How to Collect Up To $5,917/mo From Trump’s Made In USA Boom (Ad) 
|
Stocks | | |
You've undoubtedly seen the headlines covering cryptocurrencies as they soar to highs or violently crash to lows. Hardly a day goes by without some news about cryptocurrency as celebrities, athletes, actors and influencers have gotten into the fray. While they have become mainstream as a topic, ma... Read the Full Story |
|
From Our Partners | | We’ve got seven great summertime plays for you. These stocks are in a prime position to reward your portfolio… especially if you take action before summer is in full swing!
They cover summer-centric industries such as solar, home improvement, entertainment, travel, and more.
To keep you motivated during these summer months, we’d like to give you a FREE report revealing these companies – 7 Best Stocks to Own in Summer 2025. | | Get Your Copy of "7 Best Stocks to Own in Summer 2025" Here. |
|
Stocks | | |
When geopolitical tensions rise, defense contractor stocks often surge in response. These stocks are sensitive to international conflicts and national security developments, making them potent investment options. Here’s a deeper dive into what defense stocks are and how you can wisely invest... Read the Full Story |
|
Stocks | | |
Dell Technologies Inc (NYSE: DELL), The Trade Desk Inc. (NASDAQ: TTD) and Apollo Global Management Inc. (NYSE: APO) represent a diverse group of companies but have something in common: They're large-cap stocks that aren’t part of the S&P 500 but are outperforming the index.
... Read the Full Story |
|
From Our Partners | | Tesla's About to Prove Everyone Wrong... Again
Back in 2018, when Jeff Brown told everyone to buy Tesla…
The "experts" said Elon was finished and Tesla was headed for bankruptcy.
Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. | | Click here to see why Tesla's about to prove everyone wrong... again. |
|
Markets | | |
Analysts' activity in Q1 is robust, with results from Q4 outpacing estimates and guidance for tech stocks at least, leading them to raise their targets. As active as the analysts have been, the market leaders and the stocks getting the most upgrades remain the same. The rankings have been juggled,... Read the Full Story |
|
Stocks | | | Wall Street closed out its second straight losing week Friday, giving back some of the gains that helped push the stock market to an all-time high earlier in the week. The S&P 500 fell 0.6%, its third straight loss. The benchmark index hit a record high on Tuesday, but mostly wavered in the days... Read the Full Story |
|
From Our Partners | | New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun.
Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation. | | See Altucher’s Trump crypto prediction here |
|
Markets | | |
For a stock that has led its peers for so long, Southwest Airlines Company (NYSE: LUV) has been having a tough time recently. While it was able to catch some of those gains that have been sweeping across equities since November, this week’s 20% drop has given up much of t... Read the Full Story |
|
Markets | | | China’s markets regulator on Friday renewed its efforts to pep up the stock market, pledging to raise the quality of companies listed on domestic markets. The China Securities Regulatory Commission issued draft guidelines to more strictly vet applications for share listings and to more closely overs... Read the Full Story |
|
Markets | | | Americans picked up their spending a bit in February after pulling back the previous month. But last month’s gain was weaker than expected, and January’s decline was revised even lower, suggesting that many are growing more cautious with their money.Retail sales rose 0.6% last month after falling a ... Read the Full Story |
|
Markets | | | Dollar Tree swung to a surprise fourth-quarter loss and will close nearly 1,000 stores after the discount retailer slashed the value of a rival chain it acquired almost a decade ago.Dollar Tree plans to close about 600 Family Dollar stores in the first half of this year and 370 Family Dollar and 30 ... Read the Full Story |
|
Markets | | | Lori Shelton can't fathom ever having the money to buy a home — and that's a major reason why so many voters feel down on the economy ahead of this year's presidential election.Shelton, 67, drives an Uber to help pay rent in Aurora, Colorado. An advance on her pay covered her apartment's security de... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC. | | View Today's Stock Pick |
|
